# Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

> **NCT03739931** · PHASE1 · COMPLETED · sponsor: **ModernaTX, Inc.** · enrollment: 134 (actual)

## Conditions studied

- Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
- Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma

## Interventions

- **BIOLOGICAL:** mRNA-2752
- **BIOLOGICAL:** Durvalumab

## Key facts

- **NCT ID:** NCT03739931
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-27
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03739931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03739931, "Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03739931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*